<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-216
Date of Submission: 2025-07-28

This report was submitted by a Other Healthcare Professional from Baker-Moon Medical Center concerning patient ANON-PX-6756. The subject is a 33-year-old other with a significant medical history including coronary artery disease, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Subcutaneous route at a dosage of 379mg, initiated on 2025-05-28 for Hypertension with the course ongoing.

On approximately 2025-07-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Angioedema. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed eight and advised month. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-216
report_date: '2025-07-28'
patient_details:
  patient_id: ANON-PX-6756
  gender: Other
  relevant_history:
  - coronary artery disease
  - osteoarthritis
  age_at_reaction: 33
suspected_drugs:
- drug_name: Lisinopril
  dosage: 379mg
  route_of_administration: Subcutaneous
  start_date: '2025-05-28'
  indication_for_use: Hypertension
  drug_class: ACE inhibitor
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2025-07-18'
  severity: Severe
  outcome: Unknown
  intervention_required: false
- symptom_name: Angioedema
  onset_date: '2025-07-18'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed eight and advised month.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 6
reporting_facility: Baker-Moon Medical Center
reporter_type: Other Healthcare Professional
